Device Trial Radar · NCT07349121
OPTION-EMEA Clinical Trial
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jun 18, 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case. The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.
Conditions
- Atrial Fibrillation (AF)
- Stroke Prevention in Patients With Atrial Fibrillation
- Left Atrial Appendage Closure
- Pulsed Field Ablation
- Atrial Fibrillation Ablation Procedure
- Concomitant Procedures
Interventions
Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional caseDevice
left atrial appendage closure
Concomitant Pulsed Field Ablation and Left Atrial Appendage ClosureProcedure
FARAPULSE PFA and WATCHMAN FLX Pro or WATCHMAN FLX in one interventional case.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety Endpoint (PSE): Device or Procedure Related Serious Adverse EventsTime frame: 30 days following the index procedure.
- Primary Efficacy Endpoint (PEE): Acute Treatment SuccessTime frame: Through 30 days
Locations
11 sites in 5 countries. Site status is shown where the registry gives one.
AZORG - Hospital
Aalst, Belgium · Recruiting
UZ Brussel (AZ VUB)
Brussels, Belgium · Recruiting
Klinicki bolnicki centar Zagreb
Zagreb, Croatia · Recruiting
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.